<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EMLA- lidocaine and prilocaine cream </strong><br>APP Pharmaceuticals, LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a6a8a122-945d-4112-8d89-4adc98c8ce6e"></a><a name="section-1"></a><p></p>
<h1></h1>
<br><br><p class="First"><img alt="App Pharma logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=address-band-logo.jpg"></p>
<p>451096A-Revised: November 2008</p>
<p><span class="Bold Italics"><span class="Emphasis">EMLA<span class="Sup">® </span></span></span><span class="Italics"><span class="Emphasis">CREAM</span></span> (<span class="Italics"><span class="Emphasis">lidocaine 2.5% and prilocaine
                                    2.5%)</span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="fcffc801-1129-4958-9fee-b03397b16784"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">EMLA Cream (lidocaine 2.5% and prilocaine 2.5%)
                            is an emulsion in which the oil phase is a eutectic mixture of lidocaine
                            and prilocaine in a ratio of 1:1 by weight.  This eutectic
                            mixture has a melting point below room temperature and therefore both
                            local anesthetics exist as a liquid oil rather than as crystals.
                             It is packaged in 5 gram and 30 gram tubes. 
                            Lidocaine is chemically designated as acetamide,
                            2-(diethylamino)-N-(2,6-dimethylphenyl), has an octanol: water partition
                            ratio of 43 at pH 7.4, and has the following structure:</p>
<p><img alt="EMLA Chemical Structure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=emlacream-image-01.jpg"></p>
<p>Prilocaine is chemically designated as propanamide,
                            N-(2-methylphenyl)-2-(propylamino), has an octanol: water partition
                            ratio of 25 at pH 7.4, and has the following structure:</p>
<p><img alt="EMLA Chemical Structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=emlacream-image-02.jpg"></p>
<br><p>Each gram of EMLA Cream contains lidocaine 25 mg, prilocaine 25
                            mg, polyoxyethylene fatty acid esters (as emulsifiers),
                            carboxypolymethylene (as a thickening agent), sodium hydroxide to adjust
                            to a pH approximating 9, and purified water to 1 gram.  EMLA
                            Cream contains no preservative, however it passes the USP antimicrobial
                            effectiveness test due to the pH. The specific gravity of EMLA
                            Cream is 1.00.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="bd0bdf06-1fc1-4279-90c5-4cfdba433eb3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="c15cbc71-48c0-433a-914d-dcff434ad6cf"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action:</h2>
<p class="First">EMLA Cream (lidocaine 2.5% and prilocaine
                                    2.5%), applied to intact skin under occlusive dressing,
                                    provides dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> by the release of lidocaine and
                                    prilocaine from the cream into the epidermal and dermal layers
                                    of the skin and by the accumulation of lidocaine and prilocaine
                                    in the vicinity of dermal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> receptors and nerve endings.
                                     Lidocaine and prilocaine are amide-type local
                                    anesthetic agents.  Both lidocaine and prilocaine
                                    stabilize neuronal membranes by inhibiting the ionic fluxes
                                    required for the initiation and conduction of impulses, thereby
                                    effecting local anesthetic action.</p>
<br><p>The onset, depth and duration of dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> on
                                    intact skin provided by EMLA Cream depend primarily on the
                                    duration of application.  To provide sufficient
                                    <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> for clinical procedures such as intravenous catheter
                                    placement and venipuncture, EMLA Cream should be applied under
                                    an occlusive dressing for at least 1 hour.  To provide
                                    dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> for clinical procedures such as split skin
                                    graft harvesting, EMLA Cream should be applied under occlusive
                                    dressing for at least 2 hours.  Satisfactory dermal
                                    <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is achieved 1 hour after application, reaches maximum
                                    at 2 to 3 hours, and persists for 1 to 2 hours after
                                    removal.  Absorption from the genital mucosa is more
                                    rapid and onset time is shorter (5 to 10 minutes) than after
                                    application to intact skin.  After a 5 to 10 minute
                                    application of EMLA Cream to female genital mucosa, the average
                                    duration of effective <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> to an argon laser stimulus
                                    (which produced a sharp, pricking <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) was 15 to 20 minutes
                                    (individual variations in the range of 5 to 45 minutes).</p>
<br><p>Dermal application of EMLA Cream may cause a transient,
                                    local <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">blanching</span> followed by a transient, local <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or
                                    <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ddf9e30a-6902-495e-8317-2eef42d1e8f7"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics:</h2>
<p class="First">EMLA Cream is a eutectic mixture of lidocaine
                                    2.5% and prilocaine 2.5% formulated as an oil in
                                    water emulsion.  In this eutectic mixture, both
                                    anesthetics are liquid at room temperature (see <span class="Bold"><span class="Emphasis"><a href="#fcffc801-1129-4958-9fee-b03397b16784">DESCRIPTION</a></span></span>) and the penetration and subsequent
                                    systemic absorption of both prilocaine and lidocaine are
                                    enhanced over that which would be seen if each component in
                                    crystalline form was applied separately as a 2.5%
                                    topical cream.</p>
<br><p><span class="Italics"><span class="Emphasis">Absorption: </span></span>The amount of lidocaine and prilocaine systemically
                                    absorbed from EMLA Cream is directly related to both the
                                    duration of application and to the area over which it is
                                    applied.  In two pharmacokinetic studies, 60 g of EMLA
                                    Cream (1.5 g lidocaine and 1.5 g prilocaine) was applied to 400
                                        cm<span class="Sup">2</span> of intact skin on the lateral thigh and then
                                    covered by an occlusive dressing.  The subjects were
                                    then randomized such that one-half of the subjects had the
                                    occlusive dressing and residual cream removed after 3 hours,
                                    while the remainder left the dressing in place for 24 hours.
                                     The results from these studies are summarized below.</p>
<br><br><a name="vrt1136825702231"></a><table width="580">
<caption><span>                    
                                                        
                                                   
                                        TABLE 1            
                                                    
                                                    
                                                     
                                                 Absorption
                                        of Lidocaine and Prilocaine from
                                                    
                                                      
                                        EMLA Cream: Normal Volunteers (N=16)</span></caption>
<colgroup>
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
</colgroup>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>  Maximum recommended
                                                  duration of exposure is 4 hours.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">EMLA
                                                Cream<br> (g)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Area<br>
                                                  (cm<span class="Sup">2</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Time
                                                on<br>(hrs)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Drug
                                                Content<br> (mg)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Absorbed<br> (mg)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">C<span class="Sub">max</span><br> (µg/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">T<span class="Sub">max</span><br>(hr)</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">60</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">400<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">lidocaine 1500<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">54<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4<br>
</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">prilocaine
                                                1500<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">92<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.07<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First">60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First">400</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">24<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> lidocaine
                                                1500<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">243</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.28</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> prilocaine
                                                1500<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">503</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
</tr>
</tbody>
</table>
<br><p>When 60 g of EMLA Cream was applied over 400
                                    cm<span class="Sup">2</span> for 24 hours, peak blood levels of lidocaine are
                                    approximately 1/20 the systemic toxic level. Likewise,
                                    the maximum prilocaine level is about 1/36 the toxic level.
                                     In a pharmacokinetic study, EMLA Cream was applied to
                                    penile skin in 20 adult male patients in doses ranging from 0.5
                                    g to 3.3 g for 15 minutes.  Plasma concentrations of
                                    lidocaine and prilocaine following EMLA Cream application in
                                    this study were consistently low (2.5 to 16 ng/mL for lidocaine
                                    and 2.5 to 7 ng/mL for prilocaine).  The application of
                                    EMLA Cream to broken or inflamed skin, or to 2,000
                                    cm<span class="Sup">2</span> or more of skin where more of both anesthetics
                                    are absorbed, could result in higher plasma levels that could,
                                    in susceptible individuals, produce a systemic pharmacologic
                                    response.</p>
<br><p>The absorption of EMLA Cream applied to genital mucous
                                    membranes was studied in two open-label clinical trials.
                                     Twenty-nine patients received 10 g of EMLA Cream
                                    applied for 10 to 60 minutes in the vaginal fornices.
                                     Plasma concentrations of lidocaine and prilocaine
                                    following EMLA Cream application in these studies ranged from
                                    148 to 641 ng/mL for lidocaine and 40 to 346 ng/mL for
                                    prilocaine and time to reach maximum concentration
                                    (t<span class="Sub">max</span>) ranged from 21 to 125 minutes for lidocaine
                                    and from 21 to 95 minutes for prilocaine.  These levels
                                    are well below the concentrations anticipated to give rise to
                                    systemic toxicity (approximately 5000 ng/mL for lidocaine and
                                    prilocaine).</p>
<br><p><span class="Italics"><span class="Emphasis">Distribution: </span></span>When each drug is administered intravenously, the
                                    steady-state volume of distribution is 1.1 to 2.1 L/kg (mean
                                    1.5, ±0.3 SD, n=13) for lidocaine and is 0.7 to 4.4
                                    L/kg (mean 2.6, ±1.3 SD, n=13) for prilocaine.
                                     The larger distribution volume for prilocaine produces
                                    the lower plasma concentrations of prilocaine observed when
                                    equal amounts of prilocaine and lidocaine are administered.
                                     At concentrations produced by application of EMLA
                                    Cream, lidocaine is approximately 70% bound to plasma
                                    proteins, primarily alpha-1-acid glycoprotein.  At much
                                    higher plasma concentrations (1 to 4 μg/mL of free
                                    base) the plasma protein binding of lidocaine is concentration
                                    dependent.  Prilocaine is 55% bound to plasma
                                    proteins.  Both lidocaine and prilocaine cross the
                                    placental and blood brain barrier, presumably by passive
                                    diffusion.</p>
<br><p><span class="Italics"><span class="Emphasis">Metabolism: </span></span>It is not known if lidocaine or prilocaine are
                                    metabolized in the skin.  Lidocaine is metabolized
                                    rapidly by the liver to a number of metabolites including
                                    monoethylglycinexylidide (MEGX) and glycinexylidide (GX), both
                                    of which have pharmacologic activity similar to, but less potent
                                    than that of lidocaine.  The metabolite, 2,6-xylidine,
                                    has unknown pharmacologic activity.  Following
                                    intravenous administration, MEGX and GX concentrations in serum
                                    range from 11 to 36% and from 5 to 11% of
                                    lidocaine concentrations, respectively.  Prilocaine is
                                    metabolized in both the liver and kidneys by amidases to various
                                    metabolites including <span class="Italics"><span class="Emphasis">ortho-</span></span>toluidine and N-n-propylalanine. It is not metabolized
                                    by plasma esterases.  The <span class="Italics"><span class="Emphasis">ortho-</span></span>toluidine metabolite has been shown to be carcinogenic
                                    in several animal models (see <span class="Bold"><span class="Emphasis"><a href="#bcf11e42-23dd-4eba-9ad8-61a09e3c30f8">Carcinogenesis</a></span></span> subsection of
                                    <span class="Bold"><span class="Emphasis"><a href="#d47a5581-4f41-4dca-852a-4e91910235dc">PRECAUTIONS</a></span></span>).  In addition, <span class="Italics"><span class="Emphasis">ortho-</span></span>toluidine can produce <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> following
                                    systemic doses of prilocaine approximating 8 mg/kg (see
                                    <span class="Bold"><span class="Emphasis"><a href="#ca0fdae3-1b1d-4575-9e6c-01f33d5f340c">ADVERSE REACTIONS</a></span></span>). Very young
                                    patients, patients with glucose-6-phosphate dehydrogenase
                                    deficiencies and patients taking oxidizing drugs such as
                                    antimalarials and sulfonamides are more susceptible to
                                    <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> (see <span class="Bold"><span class="Emphasis"><a href="#b42ba551-c056-45a2-9eab-6283f6a7e9f3"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></span></span> subsection of <span class="Bold"><span class="Emphasis"><a href="#d47a5581-4f41-4dca-852a-4e91910235dc">PRECAUTIONS</a></span></span>).</p>
<br><p><span class="Italics"><span class="Emphasis">Elimination: </span></span>The terminal elimination half-life of lidocaine from
                                    the plasma following IV administration is approximately 65 to
                                    150 minutes (mean 110, ±24 SD, n=13).  More
                                    than 98% of an absorbed dose of lidocaine can be
                                    recovered in the urine as metabolites or parent drug.
                                     The systemic clearance is 10 to 20 mL/min/kg (mean 13,
                                    ±3 SD, n=13).  The elimination half-life of
                                    prilocaine is approximately 10 to 150 minutes (mean 70,
                                    ±48 SD, n=13).  The systemic clearance is 18
                                    to 64 mL/min/kg (mean 38, ±15 SD, n=13).
                                     During intravenous studies, the elimination half-life
                                    of lidocaine was statistically significantly longer in elderly
                                    patients (2.5 hours) than in younger patients (1.5 hours).
                                     No studies are available on the intravenous
                                    pharmacokinetics of prilocaine in elderly patients.</p>
<br><p><span class="Italics"><span class="Emphasis">Pediatrics: </span></span>Some pharmacokinetic (PK) data are available in
                                    infants (1 month to &lt;2 years old) and children (2 to
                                    &lt;12 years old).  One PK study was conducted in 9
                                    full-term neonates (mean age: 7 days and mean gestational age:
                                    38.8 weeks).  The study results show that neonates had
                                    comparable plasma lidocaine and prilocaine concentrations and
                                    blood methemoglobin concentrations as those found in previous
                                    pediatric PK studies and clinical trials.  There was a
                                    tendency towards an increase in methemoglobin formation.
                                     However, due to assay limitations and very little
                                    amount of blood that could be collected from neonates, large
                                    variations in the above reported concentrations were found.</p>
<p><span class="Italics"><span class="Emphasis"> </span></span></p>
<p><span class="Italics"><span class="Emphasis">Special Populations:
                                        </span></span>No specific PK studies were conducted.  The
                                    half-life may be increased in cardiac or hepatic dysfunction.
                                     Prilocaine’s half-life also may be increased
                                    in hepatic or renal dysfunction since both of these organs are
                                    involved in prilocaine metabolism.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="f34c63d0-9942-4404-a3d9-601d9672ab99"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">EMLA Cream application in adults prior to IV cannulation or
                            venipuncture was studied in 200 patients in four clinical studies in
                            Europe. Application for at least 1 hour provided significantly more
                            dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> than placebo cream or ethyl chloride. EMLA
                            Cream was comparable to subcutaneous lidocaine, but was less efficacious
                            than intradermal lidocaine. Most patients found EMLA Cream treatment
                            preferable to lidocaine infiltration or ethyl chloride spray.</p>
<br><p>EMLA Cream was compared with 0.5% lidocaine infiltration
                            prior to skin graft harvesting in one open label study in 80 adult
                            patients in England. Application of EMLA Cream for 2 to 5
                            hours provided dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> comparable to lidocaine infiltration.</p>
<br><p>EMLA Cream application in children was studied in seven non-US
                            studies (320 patients) and one US study (100 patients). In
                            controlled studies, application of EMLA Cream for at least 1 hour with
                            or without presurgical medication prior to needle insertion provided
                            significantly more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> reduction than placebo. In children
                            under the age of seven years, EMLA Cream was less effective than in
                            older children or adults.</p>
<br><p>EMLA Cream was compared with placebo in the laser treatment of
                            facial port-wine stains in 72 pediatric patients (ages 5 to 16).
                            EMLA Cream was effective in providing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief during laser
                            treatment.</p>
<br><p>EMLA Cream alone was compared with EMLA Cream followed by
                            lidocaine infiltration and lidocaine infiltration alone prior to
                            cryotherapy for the removal of male <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>. The data
                            from 121 patients demonstrated that EMLA Cream was not effective as a
                            sole anesthetic agent in managing the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from the surgical procedure.
                            The administration of EMLA Cream prior to lidocaine
                            infiltration provided significant relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with
                            local anesthetic infiltration and thus was effective in the overall
                            reduction of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from the procedure only when used in conjunction with
                            local anesthetic infiltration of lidocaine.</p>
<br><p>EMLA Cream was studied in 105 full term neonates (gestational
                            age: 37 weeks) for blood drawing and circumcision procedures.
                             When considering the use of EMLA Cream in neonates, the
                            primary concerns are the systemic absorption of the active ingredients
                            and the subsequent formation of methemoglobin.  In clinical
                            studies performed in neonates, the plasma levels of lidocaine,
                            prilocaine, and methemoglobin were not reported in a range expected to
                            cause clinical symptoms.</p>
<p>Local dermal effects associated with EMLA Cream application in
                            these studies on intact skin included paleness, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and
                            were transient in nature (see <span class="Bold"><span class="Emphasis"><a href="#ca0fdae3-1b1d-4575-9e6c-01f33d5f340c">ADVERSE
                            REACTIONS</a></span></span>).</p>
<br><p>The application of EMLA Cream on genital mucous membranes for
                            minor, superficial surgical procedures (eg, removal of condylomata
                            acuminata) was studied in 80 patients in a placebo-controlled clinical
                            trial (60 patients received EMLA Cream and 20 patients received
                            placebo).  EMLA Cream (5 to 10 g) applied between 1 and 75
                            minutes before surgery, with a median time of 15 minutes, provided
                            effective local anesthesia for minor superficial surgical procedures.
                             The greatest extent of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, as measured by VAS scores,
                            was attained after 5 to 15 minutes’ application.  The
                            application of EMLA Cream to genital mucous membranes as pretreatment
                            for local anesthetic infiltration was studied in a double-blind,
                            placebo-controlled study in 44 female patients (21 patients received
                            EMLA Cream and 23 patients received placebo) scheduled for infiltration
                            prior to a surgical procedure of the external vulva or genital mucosa.
                             EMLA Cream applied to the genital mucous membranes for 5 to 10
                            minutes resulted in adequate topical anesthesia for local anesthetic
                            injection.  </p>
<div class="Section" data-sectionCode="34092-7">
<a name="b9ceaea3-1ce9-4665-b3e4-972733069803"></a><a name="section-4.1"></a><p></p>
<h2>Individualization of Dose:</h2>
<p class="First">The dose of EMLA Cream that provides effective <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>
                                    depends on the duration of the application over the treated
                                    area.</p>
<br><p>All pharmacokinetic and clinical studies employed a thick
                                    layer of EMLA Cream (1 to 2 g/10 cm<span class="Sup">2</span>). The
                                    duration of application prior to venipuncture was 1 hour. The
                                    duration of application prior to taking split thickness skin
                                    grafts was 2 hours. A thinner application has not been studied
                                    and may result in less complete <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or a shorter duration
                                    of adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
<br><p>The systemic absorption of lidocaine and prilocaine is a
                                    side effect of the desired local effect. The amount of drug
                                    absorbed depends on surface area and duration of application.
                                    The systemic blood levels depend on the amount absorbed and
                                    patient size (weight) and the rate of systemic drug elimination.
                                    Long duration of application, large treatment area small
                                    patients, or impaired elimination may result in high blood
                                    levels. The systemic blood levels are typically a small fraction
                                    (1/20 to 1/36) of the blood levels that produce toxicity. Table
                                    2 below gives maximum recommended doses, application areas and
                                    application times for infants and children.</p>
<br><br><a name="vrt1136825702233"></a><table width="700">
<caption><span>                    
                                                        
                                                   
                                                   Table
                                        2
                                                            
                                                        
                                                   
                                                   EMLA
                                        CREAM MAXIMUM RECOMMENDED DOSE, APPLICATION AREA,
                                                   
                                                   
                                               AND
                                        APPLICATION TIME BY AGE AND WEIGHT*
                                                   
                                                   
                                                   
                                                   
                                                   
                                                   For
                                        Infants and Children
                                                   
                                                   
                                                   
                                                   Based
                                        on Application to Intact Skin </span></caption>
<colgroup>
<col align="center" width="35%">
<col align="center" width="25%">
<col align="center">
<col align="center">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Age and Body Weight<br>
                                                Requirements<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Maximum Total<br>
                                                Dose of EMLA Cream</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Maximum Application
                                                Area**</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Maximum Application
                                            Time</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0 up to 3 months or &lt; 5
                                                  kg<br><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1g</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10 cm<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 hour</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 up to 12 months and &gt; 5
                                                  kg<br><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2g</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 cm<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 hours</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 to 6 years and &gt; 10
                                                kg<br><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10g</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">100 cm<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 hours</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7 to 12 years and &gt; 20
                                                  kg<br><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20g</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200 cm<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 hours</p></td>
</tr>
</tbody>
</table>
<p>Please note: If a patient greater than 3 months old does
                                    not meet the minimum weight requirement, the maximum total dose
                                    of EMLA Cream should be restricted to that which corresponds to
                                    the patient’s<span class="Bold"><span class="Emphasis"> weight</span></span>.</p>
<p>* These are broad guidelines for avoiding
                                    systemic toxicity in applying EMLA Cream to patients with normal
                                    intact skin and with normal renal and hepatic function.</p>
<p>** For more individualized calculation of how
                                    much lidocaine and prilocaine may be absorbed, physicians can
                                    use the following estimates of lidocaine and prilocaine
                                    absorption for children and adults: <br><br>        The
                                    estimated mean (±SD) absorption of lidocaine is 0.045
                                    (±0.016)
                                    mg/cm2/hr.<br>        The
                                    estimated mean (±SD) absorption of prilocaine is 0.077
                                    (±0.036) mg/cm2/hr.<br></p>
<br><p>An I.V. antiarrhythmic dose of lidocaine is 1 mg/kg (70
                                    mg/70 kg) and gives a blood level of about 1µg/mL.
                                    Toxicity would be expected at blood levels above 5
                                    µg/mL. Smaller areas of treatment are recommended in a
                                    debilitated patient, a small child or a patient with impaired
                                    elimination. Decreasing the duration of application is likely to
                                    decrease the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="d17308a5-dd85-4277-8953-525e21350c5d"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">EMLA Cream (a eutectic mixture of lidocaine 2.5% and
                            prilocaine 2.5%) is indicated as a topical anesthetic for use
                            on:</p>
<p>     – <span class="Bold"><span class="Emphasis">normal intact skin </span></span>for local <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
<p>     – <span class="Bold"><span class="Emphasis">genital mucous membranes </span></span>for superficial minor surgery and as pretreatment for
                            infiltration anesthesia.</p>
<br><p>EMLA Cream is not recommended in any clinical situation when
                            penetration or migration beyond the tympanic membrane into the middle
                            ear is possible because of the ototoxic effects observed in animal
                            studies (see <span class="Bold"><span class="Emphasis"><a href="#c05e6497-8ccb-4e10-9fab-37eb9004b2c0">WARNINGS</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="e6a3d1e2-b860-4e34-99eb-fa934501fa9c"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">EMLA Cream (lidocaine 2.5% and prilocaine 2.5%)
                            is contraindicated in patients with a known history of sensitivity to
                            local anesthetics of the amide type or to any other component of the
                            product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="c05e6497-8ccb-4e10-9fab-37eb9004b2c0"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Application of EMLA Cream to larger areas or for longer times
                            than those recommended could result in sufficient absorption of
                            lidocaine and prilocaine resulting in serious adverse effects (see
                            <span class="Bold"><span class="Emphasis"><a href="#b9ceaea3-1ce9-4665-b3e4-972733069803">Individualization of Dose</a></span></span>).</p>
<p>Patients treated with class III anti-arrhythmic drugs (et,
                            amiodarone, bretylium, sotalol, dofetilide) should be under close
                            surveillance and ECG monitoring considered, because cardiac effects may
                            be additive.</p>
<p>Studies in laboratory animals (guinea pigs) have shown that EMLA
                            Cream has an ototoxic effect when instilled into the middle ear. In
                            these same studies, animals exposed to EMLA Cream only in the external
                            auditory canal, showed no abnormality. EMLA Cream should not be used in
                            any clinical situation when its penetration or migration beyond the
                            tympanic membrane into the middle ear is possible.</p>
<div class="Section" data-sectionCode="34071-1">
<a name="b42ba551-c056-45a2-9eab-6283f6a7e9f3"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span>:</h2>
<p class="First">EMLA Cream should not be used in those rare patients with
                                    congenital or idiopathic <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> and in infants under
                                    the age of twelve months who are receiving treatment with
                                    methemoglobin-inducing agents.</p>
<p>Very young patients or patients with glucose-6-phosphate
                                    dehydrogenase deficiencies are more susceptible to
                                    <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
<p>Patients taking drugs associated with drug-induced
                                    <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> such as sulfonamides, acetaminophen,
                                    acetanilid, aniline dyes, benzocaine, chloroquine, dapsone,
                                    naphthalene, nitrates and nitrites, nitrofurantoin,
                                    nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic
                                    acid, phenacetin, phenobarbital, phenytoin, primaquine, quinine,
                                    are also at greater risk for developing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
<p>There have been reports of significant <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>
                                    (20 to 30%) in infants and children following excessive
                                    applications of EMLA Cream. These cases involved the use of
                                    large doses, larger than recommended areas of application, or
                                    infants under the age of 3 months who did not have fully mature
                                    enzyme systems. In addition, a few of these cases involved the
                                    concomitant administration of methemoglobin-inducing agents.
                                    Most patients recovered spontaneously after removal of the
                                    cream. Treatment with IV methylene blue may be effective if
                                    required.</p>
<p>Physicians are cautioned to make sure that parents or
                                    other caregivers understand the need for careful application of
                                    EMLA Cream, to ensure that the doses and areas of application
                                    recommended in Table 2 are not exceeded (especially in children
                                    under the age of 3 months) and to limit the period of
                                    application to the minimum required to achieve the desired
                                    anesthesia.</p>
<p>Neonates and infants up to 3 months of age should be
                                    monitored for Met-Hb levels before, during, and after the
                                    application of EMLA Cream, provided the test results can be
                                    obtained quickly.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d47a5581-4f41-4dca-852a-4e91910235dc"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="da5a443e-cf5c-4b1f-8b9f-8f936895b3a4"></a><a name="section-8.1"></a><p></p>
<h2>General:</h2>
<p class="First">Repeated doses of EMLA Cream may increase blood levels of
                                    lidocaine and prilocaine.  EMLA Cream should be used
                                    with caution in patients who may be more sensitive to the
                                    systemic effects of lidocaine and prilocaine including acutely
                                    ill, debilitated, or elderly patients.</p>
<br><p>EMLA cream should not be applied to open <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>.</p>
<br><p>Care should be taken not to allow EMLA cream to come in
                                    contact with the eye because animal studies have demonstrated
                                    severe <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>.  Also the loss of protective
                                    reflexes can permit corneal irritation and potential <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasion</span>.
                                     Absorption of EMLA Cream in conjunctival tissues has
                                    not been determined.  If eye contact occurs,
                                    immediately wash out the eye with water or saline and protect
                                    the eye until sensation returns. </p>
<br><p>Patients allergic to paraaminobenzoic acid derivatives
                                    (procaine, tetracaine, benzocaine, etc.) have not shown cross
                                    sensitivity to lidocaine and/or prilocaine, however, EMLA Cream
                                    should be used with caution in patients with a history of drug
                                    sensitivities, especially if the etiologic agent is uncertain.</p>
<br><p>Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, because of their
                                    inability to metabolize local anesthetics normally, are at
                                    greater risk of developing toxic plasma concentrations of
                                    lidocaine and prilocaine.</p>
<br><p>Lidocaine and prilocaine have been shown to inhibit viral
                                    and bacterial growth.  The effect of EMLA Cream on
                                        <span class="Bold"><span class="Emphasis">intradermal </span></span>injections of <span class="Bold"><span class="Emphasis">live </span></span>vaccines has not been determined.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="fb0ab59f-8c45-47e8-b956-e9fca342aabb"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">When EMLA Cream is used, the patient should be aware that
                                    the production of dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> may be accompanied by the
                                    block of all sensations in the treated skin.  For this
                                    reason, the patient should avoid inadvertent <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> to the
                                    treated area by scratching, rubbing, or exposure to extreme hot
                                    or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperatures until complete sensation has returned.</p>
<br><p>EMLA cream should not be applied near the eyes or on open
                                    <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ecea20c8-baa3-4fd8-939b-c16ab2f64885"></a><a name="section-8.3"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">EMLA Cream should be used with caution in patients
                                    receiving Class I antiarrhythmic drugs (such as tocainide and
                                    mexiletine) since the toxic effects are additive and potentially
                                    synergistic.</p>
<br><p><span class="Bold"><span class="Emphasis">Prilocaine may contribute to
                                            the formation of methemoglobin in patients treated with
                                            other drugs known to cause this condition </span></span>(see <span class="Bold"><span class="Emphasis"><a href="#b42ba551-c056-45a2-9eab-6283f6a7e9f3"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></span></span> subsection of <span class="Bold"><span class="Emphasis"><a href="#c05e6497-8ccb-4e10-9fab-37eb9004b2c0">WARNINGS</a></span></span>).</p>
<br><p>Specific interaction studies with lidocaine/prilocaine
                                    and class III anti-arrhythmic drugs (eg, amiodarone, bretylium,
                                    sotalol, doetilide) have not been performed, but caution is
                                    advised (see <span class="Bold"><span class="Emphasis"><a href="#c05e6497-8ccb-4e10-9fab-37eb9004b2c0">WARNINGS</a></span></span>).</p>
<br><p>Should EMLA Cream be used concomitantly with other
                                    products containing lidocaine and/or prilocaine, cumulative
                                    doses from all formulations must be considered.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="bcf11e42-23dd-4eba-9ad8-61a09e3c30f8"></a><a name="section-8.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Carcinogenesis: </span></span>Long-term studies in animals designed to evaluate the
                                    carcinogenic potential of lidocaine and prilocaine have not been
                                    conducted.</p>
<br><p>Metabolites of prilocaine have been shown to be
                                    carcinogenic in laboratory animals.  In the animal
                                    studies reported below, doses or blood levels are compared with
                                    the Single Dermal Administration (SDA) of 60 g of EMLA Cream to
                                    400 cm<span class="Sup">2</span> for 3 hours to a small person (50 kg).
                                     The typical application of EMLA Cream for one or two
                                    treatments for venipuncture sites (2.5 or 5 g) would be 1/24 or
                                    1/12 of that dose in an adult or about the same mg/kg dose in an
                                    infant.</p>
<br><p>Chronic oral toxicity studies of <span class="Italics"><span class="Emphasis">ortho-</span></span>toluidine, a metabolite of prilocaine, in mice (450 to
                                    7200 mg/m<span class="Sup">2</span>; 60 to 960 times SDA) and rats (900 to
                                    4,800 mg/m<span class="Sup">2</span>; 60 to 320 times SDA) have shown that
                                        <span class="Italics"><span class="Emphasis">ortho-</span></span>toluidine is a carcinogen in both species.
                                     The tumors included hepatocarcinomas/<span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in
                                    female mice, multiple occurrences of
                                    <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcomas</span>/<span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> in both sexes of mice, <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> of
                                    multiple organs, transitional-cell carcinomas/<span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> of
                                    urinary bladder in both sexes of rats, subcutaneous
                                    <span class="product-label-link" type="condition" conceptid="4012174" conceptname="Fibroma">fibromas</span>/<span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcomas</span> and <span class="product-label-link" type="condition" conceptid="4033891" conceptname="Mesothelioma">mesotheliomas</span> in male rats, and
                                    mammary gland fibroadenomas/<span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in female rats.
                                     The lowest dose tested (450 mg/m<span class="Sup">2</span> in mice,
                                    900 mg/m<span class="Sup">2</span> in rats; 60 times SDA) was carcinogenic in
                                    both species.  Thus the no-effect dose must be less
                                    than 60 times SDA.  The animal studies were conducted
                                    at 150 to 2,400 mg/kg in mice and at 150 to 800 mg/kg in rats.
                                     The dosages have been converted to mg/m<span class="Sup">2</span>
                                    for the SDA calculations above.</p>
<br><p><span class="Italics"><span class="Emphasis">Mutagenesis: </span></span>The mutagenic potential of lidocaine HCl has been
                                    tested in a bacterial reverse (Ames) assay in <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>, an in
                                    vitro chromosomal aberration assay using human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> an in
                                    vivo micronucleus test in mice<span class="Italics"><span class="Emphasis">.  </span></span>There was no indication of mutagenicity or structural
                                    damage to chromosomes in these tests.</p>
<br><p><span class="Italics"><span class="Emphasis">Ortho-</span></span>toluidine, a metabolite of prilocaine, at a
                                    concentration of 0.5 μg/mL, was genotoxic in <span class="Italics"><span class="Emphasis">Escherichia coli </span></span>DNA repair and phage-induction assays.  Urine
                                    concentrates from rats treated with <span class="Italics"><span class="Emphasis">ortho-</span></span>toluidine (300 mg/kg orally; 300 times SDA) were
                                    mutagenic when examined in <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium
                                        </span></span>in the presence of metabolic activation.
                                     Several other tests on <span class="Italics"><span class="Emphasis">ortho-</span></span>toluidine, including reverse mutations in five
                                    different <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium
                                        </span></span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> in the presence or absence of metabolic
                                    activation and a study to detect single strand breaks in DNA of
                                    V79 Chinese hamster cells, were negative.</p>
<br><p><span class="Italics"><span class="Emphasis">Impairment of Fertility:
                                        </span></span>See <span class="Bold"><span class="Emphasis"><a href="#f6f0f3d7-026e-44ed-8708-22fc40685475">Use in
                                        Pregnancy</a></span></span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="f6f0f3d7-026e-44ed-8708-22fc40685475"></a><a name="section-8.5"></a><p></p>
<h2>Use in Pregnancy: Teratogenic Effects: Pregnancy Category B.</h2>
<p class="First">Reproduction studies with lidocaine have been performed
                                    in rats and have revealed no evidence of harm to the fetus (30
                                    mg/kg subcutaneously; 22 times SDA).  Reproduction
                                    studies with prilocaine have been performed in rats and have
                                    revealed no evidence of impaired fertility or harm to the fetus
                                    (300 mg/kg intramuscularly; 188 times SDA).  There are,
                                    however, no adequate and well-controlled studies in pregnant
                                    women.  Because animal reproduction studies are not
                                    always predictive of human response, EMLA Cream should be used
                                    during pregnancy only if clearly needed.</p>
<br><p>Reproduction studies have been performed in rats
                                    receiving subcutaneous administration of an aqueous mixture
                                    containing lidocaine HCl and prilocaine HCl at 1:1 (w/w).
                                     At 40 mg/kg each, a dose equivalent to 29 times SDA
                                    lidocaine and 25 times SDA prilocaine, no teratogenic,
                                    embryotoxic or fetotoxic effects were observed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="d6202f91-f9e9-487f-9f68-409923fc3160"></a><a name="section-8.6"></a><p></p>
<h2>Labor and Delivery:</h2>
<p class="First">Neither lidocaine nor prilocaine are contraindicated in
                                    labor and delivery.  Should EMLA Cream be used
                                    concomitantly with other products containing lidocaine and/or
                                    prilocaine, cumulative doses from all formulations must be
                                    considered.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="d4bb4e4a-5737-4eac-b618-0bc8ca8dc7ec"></a><a name="section-8.7"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Lidocaine, and probably prilocaine, are excreted in human
                                    milk.  Therefore, caution should be exercised when EMLA
                                    Cream is administered to a nursing mother since the milk:plasma
                                    ratio of lidocaine is 0.4 and is not determined for
                                prilocaine.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ef3cf61d-b3b5-4f43-8dc6-5a51e3283982"></a><a name="section-8.8"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Controlled studies of EMLA Cream in children under the
                                    age of seven years have shown less overall benefit than in older
                                    children or adults.  These results illustrate the
                                    importance of emotional and psychological support of younger
                                    children undergoing medical or surgical procedures.</p>
<br><p>EMLA Cream should be used with care in patients with
                                    conditions or therapy associated with <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>
                                    (see <span class="Bold"><span class="Emphasis"><a href="#b42ba551-c056-45a2-9eab-6283f6a7e9f3"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></span></span> subsection of 
                                    <span class="Bold"><span class="Emphasis"><a href="#c05e6497-8ccb-4e10-9fab-37eb9004b2c0">WARNINGS</a></span></span>).</p>
<br><p>When using EMLA Cream in young children, especially
                                    infants under the age of 3 months, care must be taken to insure
                                    that the caregiver understands the need to limit the dose and
                                    area of application, and to prevent accidental ingestion (see <span class="Bold"><span class="Emphasis"><a href="#b763bbdf-2a51-45a3-820e-60fca9dcb0d4">DOSAGE AND
                                            ADMINISTRATION</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#b42ba551-c056-45a2-9eab-6283f6a7e9f3"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></span></span>).</p>
<br><p><span class="Bold"><span class="Emphasis">In neonates (minimum gestation
                                            age: 37 weeks) and children weighing less than 20 kg,
                                            the area and duration of application should be limited
                                            (see </span></span><span class="Bold"><span class="Emphasis"><a href="#vrt1136825702233">TABLE 2 </a></span></span>in
                                    <span class="Bold"><span class="Emphasis"><a href="#b9ceaea3-1ce9-4665-b3e4-972733069803">Individualization of Dose</a></span></span><span class="Bold"><span class="Emphasis">).</span></span></p>
<p><span class="Bold"><span class="Emphasis"> </span></span></p>
<p>Studies have not demonstrated the efficacy of EMLA Cream
                                    for heel lancing in neonates.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="e3fa50ea-526d-4a50-b15a-dde56e25e3d2"></a><a name="section-8.9"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Of the total number of patients in clinical studies of
                                    EMLA Cream, 180 were age 65 to 74 and 138 were 75 and over.
                                     No overall differences in safety or efficacy were
                                    observed between these patients and younger patients.
                                     Other reported clinical experience has not identified
                                    differences in responses between the elderly and younger
                                    patients, but greater sensitivity of some older individuals
                                    cannot be ruled out.</p>
<br><p>Plasma levels of lidocaine and prilocaine in geriatric
                                    and non-geriatric patients following application of a thick
                                    layer of EMLA Cream are very low and well below potentially
                                    toxic levels.  However, there are no sufficient data to
                                    evaluate quantitative differences in systemic plasma levels of
                                    lidocaine and prilocaine between geriatric and non-geriatric
                                    patients following application of EMLA Cream.</p>
<br><p>Consideration should be given for those elderly patients
                                    who have enhanced sensitivity to systemic absorption (see
                                    <span class="Bold"><span class="Emphasis"><a href="#d459f1c5-c9c9-4ebc-a3d2-c3d4be2ab455">PRECAUTIONS</a></span></span>).</p>
<br><p>After intravenous dosing, the elimination half-life of
                                    lidocaine is significantly longer in elderly patients (2.5
                                    hours) than in younger patients (1.5 hours). (See
                                    <span class="Bold"><span class="Emphasis"><a href="#bd0bdf06-1fc1-4279-90c5-4cfdba433eb3">CLINICAL PHARMACOLOGY</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ca0fdae3-1b1d-4575-9e6c-01f33d5f340c"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="f8936524-260a-4097-8adb-6fb49eae39f4"></a><a name="section-9.1"></a><p></p>
<h2>Localized Reactions:</h2>
<p class="First">During or immediately after treatment with EMLA Cream on
                                    intact skin, the skin at the site of treatment may develop
                                    <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or may be the locus of abnormal sensation.
                                    Rare cases of discrete purpuric or petechial reactions at the
                                    application site have been reported. Rare cases of
                                    hyperpigmentation following the use of EMLA Cream have been
                                    reported. The relationship to EMLA Cream or the underlying
                                    procedure has not been established. In clinical studies on
                                    intact skin involving over 1,300 EMLA Cream-treated subjects,
                                    one or more such local reactions were noted in 56% of
                                    patients, and were generally mild and transient, resolving
                                    spontaneously within 1 or 2 hours. There were no serious
                                    reactions that were ascribed to EMLA Cream.</p>
<br><p>Two recent reports describe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> on the foreskin in
                                    neonates about to undergo circumcision. Both neonates received
                                    1.0 g of EMLA Cream.</p>
<br><p>In patients treated with EMLA Cream on intact skin, local
                                    effects observed in the trials included: paleness (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> or
                                    <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">blanching</span>) 37%, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>) 30%,
                                    alterations in temperature sensations 7%, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>
                                    6%, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> 2% and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, less than 1%.</p>
<br><p>In clinical studies on genital mucous membranes involving
                                    378 EMLA Cream-treated patients, one or more application site
                                    reactions, usually mild and transient, were noted in 41%
                                    of patients. The most common <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> were
                                    <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> (21%), <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> (17%) and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>
                                    (10%).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b2a89864-d8c5-432a-b70b-b61036e388a1"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>:</h2>
<p class="First">Allergic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> associated with
                                    lidocaine or prilocaine can occur. They are characterized by
                                    <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. If they occur
                                    they should be managed by conventional means. The detection of
                                    sensitivity by skin testing is of doubtful value.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a43823f4-5f81-4e40-abcc-83d9034dd19f"></a><a name="section-9.3"></a><p></p>
<h2>Systemic (Dose Related) Reactions:</h2>
<p class="First">Systemic adverse reactions following appropriate use of
                                    EMLA Cream are unlikely due to the small dose absorbed (see
                                    <span class="Bold Italics"><span class="Emphasis"><a href="#ddf9e30a-6902-495e-8317-2eef42d1e8f7">Pharmacokinetics</a></span></span> subsection of  <span class="Bold"><span class="Emphasis"><a href="http://bd0bdf06-1fc1-4279-90c5-4cfdba433eb3"> CLINICAL
                                        PHARMACOLOGY</a></span></span>). Systemic adverse effects of
                                    lidocaine and/or prilocaine are similar in nature to those
                                    observed with other amide local anesthetic agents including CNS
                                    excitation and/or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (light-headedness, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>,
                                    <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>,
                                    <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, blurred or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, sensations of
                                    heat, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>,
                                    <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and arrest). Excitatory
                                    CNS reactions may be brief or not occur at all, in which case
                                    the first manifestation may be <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into
                                    <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>. Cardiovascular manifestations may include
                                    <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> leading to
                                    arrest.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="cc44b4db-f721-48ca-9970-2d2d89dfee61"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Peak blood levels following a 60 g application to 400
                            cm<span class="Sup">2</span> of intact skin for 3 hours are 0.05 to 0.16
                            μg/mL for lidocaine and 0.02 to 0.10 μg/mL for
                            prilocaine.  Toxic levels of lidocaine (&gt;5
                            μg/mL) and/or prilocaine (&gt;6 μg/mL) cause
                            decreases in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, total peripheral resistance and mean
                            arterial pressure.  These changes may be attributable to direct
                            depressant effects of these local anesthetic agents on the
                            cardiovascular system.  In the absence of massive topical
                            <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or oral ingestion, evaluation should include evaluation of
                            other etiologies for the clinical effects or overdosage from other
                            sources of lidocaine, prilocaine or other local anesthetics.
                             Consult the package inserts for parenteral Xylocaine
                            (lidocaine HCl) or Citanest (prilocaine HCl) for further information for
                            the management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b763bbdf-2a51-45a3-820e-60fca9dcb0d4"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="f4ef124b-358e-46e7-b80c-48457fc74caf"></a><a name="section-11.1"></a><p></p>
<h2>Adult Patients−Intact Skin</h2>
<p class="First">A thick layer of EMLA Cream is applied to intact skin and
                                    covered with an occlusive dressing (see  <span class="Bold"><span class="Emphasis"><a href="#eefb1f08-672c-45a7-9a12-d15cf41ffcbb">INSTRUCTIONS
                                        FOR APPLICATION</a></span></span>).</p>
<br><p><span class="Bold"><span class="Emphasis">Minor Dermal Procedures:
                                        </span></span>For minor procedures such as intravenous cannulation
                                    and venipuncture, apply 2.5 grams of EMLA Cream (1/2 the 5 g
                                    tube) over 20 to 25 cm<span class="Sup">2 </span>of skin surface for at least
                                    1 hour. In controlled clinical trials using EMLA Cream, two
                                    sites were usually prepared in case there was a technical
                                    problem with cannulation or venipuncture at the first
                                    site.</p>
<br><p><span class="Bold"><span class="Emphasis">Major Dermal Procedures:
                                        </span></span>For more painful dermatological procedures involving a
                                    larger skin area such as split thickness skin graft harvesting,
                                    apply 2 grams of EMLA Cream per 10 cm<span class="Sup">2</span> of skin and
                                    allow to remain in contact with the skin for at least 2 hours.</p>
<p><span class="Bold"><span class="Emphasis">Adult Male Genital Skin:
                                        </span></span>As an adjunct prior to local anesthetic infiltration,
                                    apply a thick layer of EMLA Cream (1 g/10 cm<span class="Sup">2</span>) to the
                                    skin surface for 15 minutes.  Local anesthetic
                                    infiltration should be performed immediately after removal of
                                    EMLA Cream.</p>
<br><p>Dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> can be expected to increase for up to 3
                                    hours under occlusive dressing and persist for 1 to 2 hours
                                    after removal of the cream. The amount of lidocaine and
                                    prilocaine absorbed during the period of application can be
                                    estimated from the information in 
                                    
                                    <span class="Bold"><span class="Emphasis"><a href="#vrt1136825702233">Table 2, **
                                        footnote</a></span></span>, in 
                                    <span class="Bold"><span class="Emphasis"><a href="#b9ceaea3-1ce9-4665-b3e4-972733069803">Individualization of Dose</a></span></span>.</p>
<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e21a4f27-3309-4c3b-a9f5-0f5f357276b8"></a><a name="section-11.2"></a><p></p>
<h2>Adult Female Patients−Genital Mucous Membranes</h2>
<p class="First">For minor procedures on the female external genitalia,
                                    such as removal of condylomata acuminata, as well as for use as
                                    pretreatment for anesthetic infiltration, apply a thick layer (5
                                    to 10 grams) of EMLA Cream for 5 to 10 minutes.</p>
<br><p>Occlusion is not necessary for absorption, but may be
                                    helpful to keep the cream in place. Patients should be lying
                                    down during the EMLA Cream application, especially if no
                                    occlusion is used. The procedure or the local anesthetic
                                    infiltration should be performed immediately after the removal
                                    of EMLA Cream.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f0c82005-39e8-4d2b-8def-50d906224a09"></a><a name="section-11.3"></a><p></p>
<h2>Pediatric Patients−Intact Skin</h2>
<p class="First">The following are the maximum recommended doses,
                                    application areas and application times for EMLA Cream based on
                                    a child’s age and weight:</p>
<a name="vrt1136825702232"></a><table width="740">
<colgroup>
<col align="center" width="35%">
<col align="center" width="25%">
<col align="center">
<col align="center">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">Age and Body
                                                Weight <br>Requirements</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Maximum Total<br>Dose
                                                of EMLA Cream</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Maximum<br> Application Area </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Maximum
                                                <br> Application Time </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0 up to 3 months or &lt; 5
                                                  kg<br><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 g</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10 cm<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 hour</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 up to 12 months and &gt; 5
                                                  kg<br><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 g</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 cm<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 hours</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 to 6 years and &gt; 10
                                                kg<br><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10 g</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">100 cm<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 hours</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7 to 12 years and &gt; 20
                                                  kg<br><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 g</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200 cm<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 hours</p></td>
</tr>
</tbody>
</table>
<br><p>Please note: If a patient greater than 3 months old does
                                    not meet the minimum weight requirement, the maximum total dose
                                    of EMLA Cream should be restricted to that which corresponds to
                                    the patient’s <span class="Bold"><span class="Emphasis">weight </span></span>(see 
                                    <span class="Bold"><span class="Emphasis"><a href="#eefb1f08-672c-45a7-9a12-d15cf41ffcbb">INSTRUCTIONS
                                        FOR APPLICATION</a></span></span>).</p>
<br><p>Practitioners should carefully instruct caregivers to
                                    avoid application of excessive amounts of EMLA Cream (see
                                    <span class="Bold"><span class="Emphasis"><a href="#d47a5581-4f41-4dca-852a-4e91910235dc">PRECAUTIONS</a></span></span>).</p>
<br><p>When applying EMLA Cream to the skin of young children,
                                    care must be taken to maintain careful observation of the child
                                    to prevent accidental ingestion of EMLA Cream or the occlusive
                                    dressing.  A secondary protective covering to prevent
                                    inadvertent disruption of the application site may be useful.</p>
<br><p><span class="Bold"><span class="Emphasis">EMLA Cream should not be used
                                            in neonates with a gestational age less than 37 weeks
                                            nor in infants under the age of 12 months who are
                                            receiving treatment with methemoglobin-inducing agents
                                            (see </span></span><span class="Bold"><span class="Emphasis"><a href="#b42ba551-c056-45a2-9eab-6283f6a7e9f3"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> </a></span></span><span class="Bold"><span class="Emphasis">subsection of </span></span><span class="Bold"><span class="Emphasis"><a href="#c05e6497-8ccb-4e10-9fab-37eb9004b2c0">WARNINGS</a></span></span><span class="Bold"><span class="Emphasis">).</span></span></p>
<p><span class="Bold"><span class="Emphasis"> </span></span></p>
<p>When EMLA Cream (lidocaine 2.5% and prilocaine
                                    2.5%) is used concomitantly with other products
                                    containing local anesthetic agents, the amount absorbed from all
                                    formulations must be considered (see <span class="Bold"><span class="Emphasis"><a href="#b9ceaea3-1ce9-4665-b3e4-972733069803">Individualization of Dose</a></span></span>).  The amount
                                    absorbed in the case of EMLA Cream is determined by the area
                                    over which it is applied and the duration of application under
                                    occlusion (see <span class="Bold"><span class="Emphasis"><a href="#vrt1136825702231">TABLE 2,
                                            ** footnote</a></span></span> in 
                                    <span class="Bold"><span class="Emphasis"><a href="#b9ceaea3-1ce9-4665-b3e4-972733069803">Individualization of Dose</a></span></span> ). <br></p>
<p>Although the incidence of systemic adverse reactions with
                                    EMLA Cream is very low, caution should be exercised,
                                    particularly when applying it over large areas and leaving it on
                                    for longer than 2 hours.  The incidence of systemic
                                    adverse reactions can be expected to be directly proportional to
                                    the area and time of exposure (see <span class="Bold"><span class="Emphasis"><a href="#b9ceaea3-1ce9-4665-b3e4-972733069803">Individualization of Dose</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="eefb1f08-672c-45a7-9a12-d15cf41ffcbb"></a><a name="section-12"></a><p></p>
<h1>INSTRUCTIONS FOR APPLICATION:</h1>
<p class="First">To measure 1 gram of EMLA, the Cream should be gently squeezed
                            out of the tube as a narrow strip that is 1.5 inches (3.8 cm) long and
                            0.2 inches (5 mm) wide.  The strip of EMLA cream should be
                            contained within the lines of the diagram shown below. </p>
<br><p><img alt="emlacream-diagram1gstrip" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=emlacream-diagram1gstrip-01.jpg"></p>
<p>     1.5 x 0.2 inches</p>
<p><br>Use the number of strips that equals your dose, like the
                            examples in the table below.</p>
<br><p>                                               
                                    
                                <span class="Underline"><span class="Emphasis">Dosing Information</span></span></p>
<p>                                                           
                             1 gram = 1 strip</p>
<p>                                                           
                            2 grams = 2 strips</p>
<p>                                               
                                   
                            2.5 grams = 2.5 strips</p>
<br><p>For adult and pediatric patients, apply ONLY as prescribed by
                            your physician.</p>
<br><p>If your child is below the age of 3 months or small for their
                            age, please inform your doctor before applying EMLA Cream, which can be
                            harmful, if applied over too much skin at one time in young children.</p>
<br><p>When applying EMLA to the intact skin of young children, it is
                            important that they be carefully observed by an adult in order to
                            prevent the accidental ingestion of or eye contact with EMLA Cream.</p>
<br><p>EMLA Cream must be applied to intact skin at least 1 hour before
                            the start of a routine procedure and for 2 hours before the start of a
                            painful procedure.  A protective covering of the cream is not
                            necessary for absorption but may be helpful to keep the cream in place.</p>
<br><p>If using a protective covering, your doctor will remove it, wipe
                            off the EMLA Cream, and clean the entire area with an antiseptic
                            solution before the procedure.  The duration of effective skin
                            anesthesia will be at least 1 hour after removal of the protective
                            covering.</p>
<br><div class="Section" data-sectionCode="34068-7">
<a name="d459f1c5-c9c9-4ebc-a3d2-c3d4be2ab455"></a><a name="section-12.1"></a><p></p>
<h2>Precautions</h2>
<p class="First"><span class="Bold"><span class="Emphasis">1. </span></span>Do not apply near eyes or open <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>.</p>
<p><span class="Bold"><span class="Emphasis">2. </span></span>Keep out of the reach of children.</p>
<p><span class="Bold"><span class="Emphasis">3. </span></span>If your child becomes very dizzy, excessively <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>,
                                    or develops duskiness of the face or lips after
                                    applying EMLA Cream, remove the cream and contact the
                                    child’s physician at once.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="fc7c5cbc-d10f-48be-b49f-9c0d191deb04"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold"><span class="Emphasis">EMLA Cream </span></span>is available as the following:</p>
<br><a name="vrt1136825702234"></a><table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">Product<br>No. </td>
<td class="Botrule Lrule Rrule Toprule" align="left">NDC<br>No. </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom">Strength</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom">Size</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">278905</td>
<td class="Botrule Lrule Rrule Toprule" align="left">63323-289-05</td>
<td class="Botrule Lrule Rrule Toprule" align="left">5 gram/tube</td>
<td class="Botrule Lrule Rrule Toprule" align="left">packaged
                                        individually.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">278955    </td>
<td class="Botrule Lrule Rrule Toprule" align="left">63323-289-55 </td>
<td class="Botrule Lrule Rrule Toprule" align="left">5
                                        gram/tube </td>
<td class="Botrule Lrule Rrule Toprule" align="left">packaged in
                                        5. </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">279030 </td>
<td class="Botrule Lrule Rrule Toprule" align="left">63323-290-30 </td>
<td class="Botrule Lrule Rrule Toprule" align="left">30
                                        gram/tube </td>
<td class="Botrule Lrule Rrule Toprule" align="left">packaged
                                        individually,  in a child-resistant
                                    tube. </td>
</tr>
</tbody>
</table>
<br><p><span class="Bold"><span class="Emphasis">NOT FOR OPHTHALMIC USE.</span></span></p>
<p><span class="Bold"><span class="Emphasis"> </span></span></p>
<p><span class="Bold"><span class="Emphasis">KEEP CONTAINER TIGHTLY CLOSED AT ALL
                                    TIMES WHEN NOT IN USE.</span></span></p>
<p><span class="Bold"><span class="Emphasis"> </span></span></p>
<p>Store at 20° to 25°C (68° to
                            77°F)[see USP Controlled Room Temperature].</p>
<p><span class="Bold"><span class="Emphasis"> </span></span></p>
<p>Manufactured for:</p>
<p><img alt="APP Pharmaceuticals logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=address-band2-logo.jpg"></p>
<p>451096A</p>
<p>Revised: November 2008</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="da7d6047-573d-4814-9715-ab80bae45910"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY -
                                    EMLA Cream 5 grams Box Label</span></span></p>
<p><span class="Bold"><span class="Emphasis"> NDC </span></span> 63323-289-05</p>
<p>278905</p>
<p><span class="Bold"><span class="Emphasis">5 Grams</span></span></p>
<p><span class="Bold"><span class="Emphasis">EMLA<span class="Sup">®</span> CREAM <br></span></span>
                            (lidocaine 2.5% and prilocaine
                                    2.5%)
                        </p>
<p>This package contains ONE 5 gram tube of
                            EMLA<span class="Sup">®</span> Cream.</p>
<p>For Topical Use Only
                        </p>
<p>Rx only
                        </p>
<p><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY - EMLA Cream 5 grams Box Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=278905-carton.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="b3e10945-e787-4606-a108-9476a385615b"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY -
                                    EMLA Cream 5 grams Tube Label</span></span></p>
<p><span class="Bold"><span class="Emphasis"> NDC </span></span> 63323-289-05</p>
<p>Rx only
                        </p>
<p><span class="Bold"><span class="Emphasis">EMLA<span class="Sup">®</span> CREAM<br></span></span> (lidocaine 2.5% and
                                    prilocaine 2.5%)
                        </p>
<p>For Topical Use Only
                        </p>
<p><span class="Bold"><span class="Emphasis">5 Grams</span></span><br></p>
<p><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY - EMLA Cream 5 grams Tube Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=278905-tube.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ae001cbe-7fa8-4ecc-b745-f040d90523d7"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY -
                                    EMLA Cream 5 grams Box Label</span></span></p>
<p><span class="Bold"><span class="Emphasis"> NDC </span></span> 63323-289-55</p>
<p>278955</p>
<p><span class="Bold"><span class="Emphasis">5 Grams</span></span></p>
<p><span class="Bold"><span class="Emphasis">EMLA<span class="Sup">®</span> CREAM<br></span></span>(lidocaine 2.5% and prilocaine
                                    2.5%)
                        </p>
<p>This package contains FIVE 5 gram tubes of
                            EMLA<span class="Sup">®</span> Cream.
                        </p>
<p>For Topical Use Only
                        </p>
<p>Rx only
                        </p>
<p><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY - EMLA Cream 5 grams Box Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=278955-carton.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="cdcb5f24-e562-4c26-8818-cea71d1f1718"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY -
                                    EMLA Cream 30 grams Box Label</span></span></p>
<p><span class="Bold"><span class="Emphasis"> NDC </span></span>63323-290-30</p>
<p>279030</p>
<p><span class="Bold"><span class="Emphasis">30 Grams</span></span></p>
<p><span class="Bold"><span class="Emphasis">EMLA<span class="Sup">®</span> CREAM</span></span><br>
                           (lidocaine 2.5% and prilocaine
                                    2.5%)
                        </p>
<p>For Topical Use Only
                        </p>
<br><br><p><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY - EMLA Cream 30 grams Box Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=279030-carton.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e12751bf-5647-4cc2-91c2-9ee602bddc98"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY -
                                    EMLA Cream 30 grams Tube Label</span></span></p>
<p><span class="Bold"><span class="Emphasis"> NDC </span></span> 63323-290-30</p>
<p>279030</p>
<p><span class="Bold"><span class="Emphasis">EMLA<span class="Sup">®</span> CREAM<br></span></span>(lidocaine 2.5% and prilocaine
                                    2.5%)
                        </p>
<p>For Topical Use Only
                        </p>
<p><span class="Bold"><span class="Emphasis">30 Grams</span></span></p>
<p>Rx only
                        </p>
<p><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY - EMLA Cream 30 grams Tube Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=823c2d42-d00d-401d-4081-fc1d434455e0&amp;name=279030-tube.jpg"></p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EMLA 		
					</strong><br><span class="contentTableReg">lidocaine cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-289</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LIDOCAINE</strong> (LIDOCAINE) </td>
<td class="formItem">LIDOCAINE</td>
<td class="formItem">25 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PRILOCAINE</strong> (PRILOCAINE) </td>
<td class="formItem">PRILOCAINE</td>
<td class="formItem">25 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-289-05</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63323-289-55</td>
<td class="formItem">5  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019941</td>
<td class="formItem">09/29/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EMLA 		
					</strong><br><span class="contentTableReg">lidocaine cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-290</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LIDOCAINE</strong> (LIDOCAINE) </td>
<td class="formItem">LIDOCAINE</td>
<td class="formItem">25 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PRILOCAINE</strong> (PRILOCAINE) </td>
<td class="formItem">PRILOCAINE</td>
<td class="formItem">25 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-290-30</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019941</td>
<td class="formItem">09/29/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AstraUSA, Inc</td>
<td class="formItem"></td>
<td class="formItem">176500158</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d0a64e03-fd5e-6a5e-00c4-de687bbf08b3</div>
<div>Set id: 823c2d42-d00d-401d-4081-fc1d434455e0</div>
<div>Version: 1</div>
<div>Effective Time: 20091005</div>
</div>
</div> <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
